SCHEMBL26035451

SCHEMBL26035451

Cc1cc2[nH]c(C)c(I)c(=O)c2cc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 2/20 0.45
GRIN3B O60391 2/20 0.45
GRIN1 Q05586 2/20 0.45
GRIN2A Q12879 2/20 0.45
GRIN2B Q13224 2/20 0.45
GRIN2C Q14957 2/20 0.45
GRIN3A Q8TCU5 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.38
HSD17B10 Q99714 1/20 0.38
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 3/20 0.37
GAA P10253 3/20 0.37
GLA P06280 2/20 0.37
HTT P42858 2/20 0.37
MAPT P10636 1/20 0.37
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5534060 0.85 GRIN2D (0.50) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL13560656 0.79 GRIN2D (0.52) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL19146293 0.78 KDM4E (0.53) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL1394736 0.73 MTNR1A (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL30462974 0.72 HTT (0.61) SMN1; SMN2HSD17B10KDM4EALDH1A1HPGD
SCHEMBL14937732 0.72 HTT (0.61) SMN1; SMN2HSD17B10KDM4EALDH1A1HPGD
SCHEMBL24335067 0.72 AHR (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL26035413 0.71 GRIN2D (0.39) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL13953176 0.70 KDM4E (0.50) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL12216212 0.69 MEN1 (0.69) SMN1; SMN2KDM4EALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731960-B2 Biheterocyclic compound Sumitomo Pharma Co., Ltd. (JP) 2023-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731960-B2 Biheterocyclic compound NR4A3, NGF, OGFR GRIN2D 1201/4885GRIN3B 185/4885GRIN1 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.